{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:52:35Z","timestamp":1790790755269,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH\/NHGRI","award":["R01HG013416 and R01HG011800"],"award-info":[{"award-number":["R01HG013416 and R01HG011800"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04833-1","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:57:59Z","timestamp":1763708279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case report"],"prefix":"10.1007","volume":"95","author":[{"given":"Madeline L.","family":"Norris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"DeRemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio D.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George P.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"4","key":"4833_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","volume":"16","author":"RB Diasio","year":"1989","unstructured":"Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16(4):215\u2013237. https:\/\/doi.org\/10.2165\/00003088-198916040-00002","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"4833_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2):210\u2013216. https:\/\/doi.org\/10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"4833_CR3","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2217\/pgs.11.72","volume":"12","author":"U Amstutz","year":"2011","unstructured":"Amstutz U, Froehlich TK, Largiad\u00e8r CR (2011) Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12(9):1321\u20131336. https:\/\/doi.org\/10.2217\/pgs.11.72","journal-title":"Pharmacogenomics"},{"key":"4833_CR4","unstructured":"National Institutes of Health, Public Health, Service H (2008) Public Teleconference Regarding Licensing and Collaborative Research Opportunities for: Methods and Compositions Relating to Detecting Dihydropyrimidine Dehydrogenase (DPD). Federal Register 73 (129)"},{"key":"4833_CR5","unstructured":"\"Safety Announcement: FDA highlights importance of DPD deficiency discussions with patients prior to capecitabine or 5FU treatment .\" Resources for Information | Approved Drugs, U.S. Food & Drug Administration(2025). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/safety-announcement-fda-highlights-importance-dpd-deficiency-discussions-patients-prior-capecitabine"},{"issue":"2","key":"4833_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101197","volume":"8","author":"M de With","year":"2023","unstructured":"de With M, Sadlon A, Cecchin E, Haufroid V, Thomas F, Joerger M, van Schaik RHN, Mathijssen RHJ, Largiad\u00e8r CR (2023) Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. ESMO Open 8(2):101197. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101197","journal-title":"ESMO Open"},{"key":"4833_CR7","doi-asserted-by":"publisher","unstructured":"Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, Turner AJ, van Schaik RHN, Whirl-Carrillo M, Weck KE, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium (2024) DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium. J Mol Diagn 26 (10):851\u2013863. https:\/\/doi.org\/10.1016\/j.jmoldx.2024.05.015","DOI":"10.1016\/j.jmoldx.2024.05.015"},{"issue":"11","key":"4833_CR8","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2217\/pgs.13.116","volume":"14","author":"S Terrazzino","year":"2013","unstructured":"Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA (2013) DPYD IVS14\u2009+\u20091G\u2009>\u2009A and 2846A\u2009>\u2009T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 14(11):1255\u20131272. https:\/\/doi.org\/10.2217\/pgs.13.116","journal-title":"Pharmacogenomics"},{"issue":"11","key":"4833_CR9","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"19","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentj\u00e9 VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM (2018) DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 19(11):1459\u20131467. https:\/\/doi.org\/10.1016\/S1470-2045(18)30686-7","journal-title":"Lancet Oncol"},{"key":"4833_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00118","volume":"1","author":"LM Henricks","year":"2017","unstructured":"Henricks LM, Kienhuis E, de Man FM, van der Veldt AAM, Hamberg P, van Kuilenburg ABP, van Schaik RHN, Lunenburg CATC, Guchelaar HJ, Schellens JHM, Mathijssen RHJ (2017) Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low-dose capecitabine. JCO Precis Oncol 1:1\u201310. https:\/\/doi.org\/10.1200\/PO.17.00118","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"4833_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","volume":"28","author":"CATC Lunenburg","year":"2020","unstructured":"Lunenburg CATC, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Swen JJ, Guchelaar HJ (2020) Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet 28(4):508\u2013517. https:\/\/doi.org\/10.1038\/s41431-019-0540-0","journal-title":"Eur J Hum Genet"},{"key":"4833_CR12","unstructured":"National Comprehensive Cancer Network I NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Name V.4.2025"},{"issue":"35","key":"4833_CR13","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1200\/JCO.22.02780","volume":"41","author":"JE Knikman","year":"2023","unstructured":"Knikman JE, Wilting TA, Lopez-Yurda M, Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Nieboer P, Droogendijk HJ, Creemers GJ, Mandigers CMPW, Imholz ALT, Mathijssen RHJ, Portielje JEA, Valkenburg-van Iersel L, Vulink A, van der Poel MHW, Baars A, Swen JJ, Gelderblom H, Schellens JHM, Beijnen JH, Guchelaar HJ, Cats A (2023) Survival of patients with cancer with survival of patients with cancer with cancer with DPYD variant alleles and Dose-Individualized fluoropyrimidine Therapy-A Matched-Pair analysis. J Clin Oncol 41(35):5411\u20135421. https:\/\/doi.org\/10.1200\/JCO.22.02780","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04833-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04833-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04833-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:58:00Z","timestamp":1763708280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04833-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4833"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04833-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DD - Non-financial compensation consultation with Astra Zeneca.; TJG - DSMB: Seagen, Nihon Medi-Physics, KAHR Medical, Arbele; Consultant: Avammune Therapeutics, BillionToOne, Exact Sciences, Summit Therapeutics; Research Support (to institution): Bristol-Myers Squibb, Merck, AstraZeneca, Lilly, Bayer, Incyte, Ipsen, Genentech, Astellas Pharma, GlaxoSmithKline, Amgen, OncoC4, BillionToOne, Jounce Therapeutics, Elicio Therapeutics, AMAL Therapeutics\/Boehringer Ingelheim, Seagen, Regeneron, Deciphera.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}